Aura Biosciences receives FDA fast track designation for belzupacap sarotalocan (AU-011) for the treatment of non-muscle invasive bladder cancer

30 June 2022 - Aura Biosciences today announced that the U.S. FDA has granted fast track designation for belzupacap sarotalocan (AU-011), ...

Read more →

Apnimed granted FDA fast track designation for AD109, a novel first in class oral pharmacologic combination for the treatment of obstructive sleep apnoea

28 June 2022 -  Additional Phase 2b data evaluating AD109 as potential treatment for obstructive sleep apnoea anticipated in Q3 ...

Read more →

Ikena Oncology receives FDA fast track designation for novel TEAD inhibitor IK-930 to treat unresectable NF2 deficient mesothelioma

22 June 2022 - Ikena Oncology today announced that the U.S. FDA has granted fast track designation for IK-930, the Company’s ...

Read more →

Paratek Pharmaceuticals’ Nuzyra receives FDA fast track designation for the treatment of pulmonary non-tuberculous mycobacterial disease caused by mycobacterium avium complex and mycobacterium abscessus

21 June 2022 - Phase 2b study in MAB pulmonary infections on-going and enrolling as planned. ...

Read more →

Kintara Therapeutics granted fast track designation from the FDA for VAL-083 for newly diagnosed glioblastoma

15 June 2022 - swire/ -- Kintara Therapeutics today announced that the United States FDA has granted fast track designation to ...

Read more →

AlgoTx’s ATX01 granted fast track designation by FDA for chemotherapy-induced neuropathic pain

9 June 2022 - AlgoTx announced today that it has received fast track designation from the U.S. FDA for the ...

Read more →

FDA grants fast track designation for BioCryst’s ALK-2 inhibitor, BCX9250

8 June 2022 - BioCryst Pharmaceuticals today announced the U.S. FDA has granted fast track designation for BCX9250 for the ...

Read more →

PDS Biotechnology granted FDA fast track designation for lead candidate PDS0101

2 June 2022 - PDS Biotech has been granted fast track designation for PDS0101 in combination with Keytruda (pembrolizumab) for ...

Read more →

Accutar Biotechnology announces fast track designation granted by FDA to AC0176 for the treatment of metastatic castration resistant prostate cancer

1 June 2022 - Accutar Biotechnology today announced that the U.S. FDA has granted fast track designation to AC0176 for ...

Read more →

Fast track designation granted to MTX110 development for the treatment of recurrent glioblastoma

1 June 2022 - Midatech Pharma is pleased to announce that upon submitting an application to the U.S. FDA, its development ...

Read more →

Priothera receives fast track designation for mocravimod in combination with allogeneic haematopoietic stem cell transplant for post remission therapy of acute myeloid leukaemia patients

31 May 2022 - Priothera today announces that the U.S. FDA has granted fast track designation for mocravimod in combination with ...

Read more →

Pfizer granted FDA fast track designation for ervogastat/clesacostat combination for the treatment of non-alcoholic steatohepatitis

26 May 2022 - Pfizer today announced the U.S. FDA has granted fast track designation to Pfizer’s investigational combination therapy ...

Read more →

Elevation Oncology announces FDA fast track designation granted to seribantumab for the tumour agnostic treatment of solid tumours harbouring NRG1 gene fusions

25 May 2022 - Elevation Oncology today announced that the U.S. FDA has granted fast track designation to seribantumab for the ...

Read more →

Blue Lake Biotechnology announces FDA fast track designation for BLB-201 intranasal RSV vaccine

24 May 2022 - Blue Lake Biotechnology today announced that the U.S. FDA has granted fast track designation for BLB-201, an ...

Read more →

Aptose receives fast track designation for HM43239 in relapsed/refractory AML patients and FLT3 mutation

4 May 2022 - Aptose Biosciences today announced that the U.S. FDA has granted fast track designation to HM43239, an oral, ...

Read more →